Desmopressin
Ddavp, Nocdurna (desmopressin) is a protein pharmaceutical. Desmopressin was first approved as Ddavp on 1982-01-01. It is used to treat enuresis, hemorrhage, neurogenic diabetes insipidus, thrombocytopenia, and von willebrand diseases in the USA. It is known to target vasopressin V1b receptor, vasopressin V2 receptor, vasopressin V1a receptor, and oxytocin receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ddavp, Nocdurna (generic drugs available since 1997-10-15, discontinued: Concentraid, Minirin, Noctiva, Stimate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ddavp | New Drug Application | 2021-07-20 |
| desmopressin acetate | ANDA | 2023-06-06 |
| nocdurna | New Drug Application | 2020-12-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| enuresis | — | D004775 | R32 |
| hemorrhage | MP_0001914 | D006470 | R58 |
| neurogenic diabetes insipidus | HP_0000863 | D020790 | — |
| thrombocytopenia | HP_0001873 | D013921 | D69.6 |
| von willebrand diseases | Orphanet_903 | D014842 | D68.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Desmopressin Acetate, Noctiva, Acerus Pharms | |||
| 9539302 | 2030-06-15 | DP | |
| 11419914 | 2030-06-15 | U-3431 | |
| 7799761 | 2024-09-26 | DP | |
| Desmopressin Acetate, Nocdurna, Ferring Pharms Inc | |||
| 9974826 | 2030-04-13 | U-2326, U-2327 | |
| 10137167 | 2029-05-21 | U-2327 | |
| 11020448 | 2029-05-21 | U-2327 | |
| 7560429 | 2024-02-02 | DP | U-2326 |
| 7947654 | 2023-12-29 | DP | |
| 8802624 | 2023-12-29 | U-2326 | |
| 9220747 | 2023-05-07 | U-2326 | |
| 9504647 | 2023-05-07 | DP | U-2326 |
| 9919025 | 2023-05-07 | U-2326 | |
| 10307459 | 2023-05-07 | DP | |
HCPCS
Code | Description |
|---|---|
| J2597 | Injection, desmopressin acetate, per 1 mcg |
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | F33.9 | 4 | — | 3 | 1 | 3 | 11 | |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | 1 | — | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 1 | 1 | — | 3 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | 1 | — | 1 | |
| Neuroaxonal dystrophies | D019150 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | 1 | — | — | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | 1 | — | — | 2 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | 1 | — | 1 | 2 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | 1 | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
| Herpes zoster | D006562 | EFO_0006510 | B02 | — | — | 1 | — | — | 1 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | 1 | — | — | 1 |
| Abdominal pain | D015746 | R10.9 | — | — | 1 | — | — | 1 | |
| Constipation | D003248 | HP_0002019 | K59.0 | — | — | 1 | — | — | 1 |
| Functional colonic diseases | D003109 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | F14 | — | 3 | — | — | — | 3 | |
| Back pain | D001416 | HP_0003418 | M54 | — | 2 | — | — | — | 2 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 2 | — | — | — | 2 |
| Dual (psychiatry) diagnosis | D017831 | — | 1 | — | — | — | 1 | ||
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | — | 1 |
| Sciatica | D012585 | HP_0011868 | M54.3 | — | 1 | — | — | — | 1 |
| Small cell lung carcinoma | D055752 | — | 1 | — | — | — | 1 | ||
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 1 | — | — | — | 1 |
| Rett syndrome | D015518 | F84.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | — | 3 | ||
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | C90.0 | — | — | — | — | 1 | 1 | |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | — | — | 1 | 1 |
| Vulvar diseases | D014845 | — | — | — | — | 1 | 1 | ||
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | — | 1 | 1 |
| Personality disorders | D010554 | HP_0012075 | F60.6 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DESMOPRESSIN |
| INN | desmopressin |
| Description | Desmopressin is a synthetic analogue of vasopressin in which 3-mercaptopropionic acid replaces the cysteine residue at position 1 and D-arginine replaces the residue at position 8. An antidiuretic, it increases urine concentration and decreases urine production, and is used (usually as the trihydrate of the acetic acid salt) to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions. It is also used in the diagnosis and treatment of cranial diabetes insipidus and in tests of renal function. It has a role as a vasopressin receptor agonist, a renal agent and a diagnostic agent. |
| Classification | Protein |
| Drug class | vasoconstrictors (vasopressin derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 16679-58-6 |
| RxCUI | 3251 |
| ChEMBL ID | CHEMBL1429 |
| ChEBI ID | 4450 |
| PubChem CID | 5311065 |
| DrugBank | DB00035 |
| UNII ID | ENR1LLB0FP (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
AVPR1B
AVPR1B
AVPR2
AVPR2
AVPR1A
AVPR1A
OXTR
OXTR
Organism
Homo sapiens
Gene name
AVPR1B
Gene synonyms
AVPR3, VPR3
NCBI Gene ID
Protein name
vasopressin V1b receptor
Protein synonyms
Antidiuretic hormone receptor 1b, arginine vasopressin receptor 3, AVPR V1b, AVPR V3, pituitary vasopressin receptor 3, V1B receptor, Vasopressin V3 receptor
Uniprot ID
Mouse ortholog
Avpr1b (26361)
vasopressin V1b receptor (Q9WU02)
Variants
Clinical Variant
No data
Financial
Noctiva - Avadel Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,365 documents
View more details
Safety
Black-box Warning
Black-box warning for: Desmopressin acetate, Nocdurna
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
595 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more